[Evaluation of the efficacy of antiparasitic drugs in the treatment of concurrent parasitic diseases in patients with HIV infection and in those with pulmonary tuberculosis].

The efficacy of albendazole (400 mg taken once), mebendazole (100 mg taken once), and metronidazole (0.5 g thrice daily for 7 days) was evaluated when treating ascariasis, enterobiosis, and blastocystosis, respectively, in patients with HIV infection and in those with pulmonary tuberculosis. Metronidazole-resistant lambliasis was treated with exdisten (5 mg four times for 10 days) in 30.4% of the patients with HIV infection and in 43.3% of those with tuberculosis. Most HIV infected patients received antiretroviral therapy (ARVT). All the tuberculosis patients took isoniazid, ethambutol, pyrazinamide, rifampicin, and streptomycin. Efficiency was monitored by triple coproscopy at an interval of 5-7 days and by additional examinations using the method of Ritchii et al. There was parasitological cure (decreased infection rate for blastocystosis) and clinical improvement as positive changes in symptoms, such as nausea, weakness, headache, weight loss, and others, in all the patients with concomitant ascariasis, enterobiosis, and lambliasis. ARVT and antituberculosis drugs were observed to be better tolerated in all cases.

[Use of lymphotropic therapy in the multimodality treatment of patients with pulmonary tuberculosis and comorbidity]. / Primenenie limfotropnoi terapii pri kompleksnom lechenii bol'nykh tuberkulezom legkikh s soputstvuiushchei patologiei.

Regional lymphotropic therapy involving 10% isoniazid administration was included into multimodality treatment in 250 patients with pulmonary tuberculosis and comorbidity. The findings have indicated that the lymphotropic therapy during the use of rifampicin, streptomycin, ethambutol enhances the efficiency of chemotherapy in different forms of pulmonary tuberculosis, including the latter concurrent with hepatic lesion or diabetes mellitus. Lymphotropic therapy is particularly beneficial to patients with poor drug tolerability. The use of lymphotropic isoniazid in the multimodality treatment of pulmonary tuberculosis leads to the earlier disappearance of the symptoms of tuberculous intoxication (by 1-1.5 months) in 80-92% of the patients, to abacillation in the same periods, to the increased frequency of decay cavity closure by an average of 15% as compared to the conventional treatment, and, in most cases, to the normalization of the biochemical parameters of hepatic function.

[Effectiveness of lymphotropic therapy in patients with tuberculosis in relations to genetic markers]. / Effektivnost' limfotropnoi terapii u bol'nykh tuberkulezom legkikh v zavisimosti ot geneticheskikh markerov.

To study whether a combination of the carriage of genetic blood markers: haptoglobin phenotypes and red blood cell glucose-6-phosphate dehydrogenase, 60 patients with destructive tuberculosis were given a new drug treatment regimen by using regional lymphotropic therapy with 10% isoniazid. The efficiency of the treatment and residual changes were found to be directly related to what a patient has as genetic background. Defining the types of combinations of genetic markers may predict the course of disease, the efficiency of treatment, and outcomes.